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RNA interference is a cellular mechanism by which small molecules of double stranded RNA modulate gene ex-
pression acting on the concentration and/or availability of a given messenger RNA. Almost 10 years after Fire 
and Mello received the Nobel Prize for the discovery of this mechanism in flat worms, RNA interference is on 
the edge of becoming a new class of therapeutics. With various phase III studies underway, the following years 
will determine whether RNAi-therapeutics can rise up to the challenge and become mainstream medicines. The 
present review gives a thorough overview of the current status of this technology focusing on the path to the clin-
ic of this new class of compounds.  
 





RNA INTERFERENCE:  
MECHANISM OF ACTION 
RNA interference (RNAi) is an evolu-
tionary conserved, endogenous process for 
post-transcriptional regulation of gene ex-
pression. Since the discovery of RNAi in C. 
elegans the mechanistic details of the RNAi 
pathway have been largely characterized. 
The discovery of RNAi fueled an extensive 
research aimed towards the application of 
this novel tool for therapeutic purposes as 
well as for further understanding of the 
mechanisms of gene regulation. These inves-
tigations led to the identification of short se-
quences of double-stranded RNAs (dsRNAs) 
as molecular mediators of RNAi (Fire et al., 
1998). With the 2001(a) report by Elbashir 
and collaborators, showing that 21-mer 
dsRNAs were able to mediate specific gene 
silencing in mammalian cells in vitro, the 
basic mechanism of RNAi became available, 
allowing the initiation of a new era in ma-
nipulation of gene expression. This new 
technology, that could potentially silence any 
gene of interest, was immediately considered 
the basis for a revolutionary new class of 
drugs, with applications in numerous diseas-
es, where deregulation of gene expression 
contributes to pathogenesis. Eukaryotic cells 
are able to modulate gene expression by 
transcribing RNAs that use the RNAi ma-
chinery to silence or repress the expression 
of specific genes. These modulators of gene 
expression are transcribed from non-coding 
regions of the genome yielding micro-RNAs 
(miRNAS) or short interfering-RNAs (siR-
NAs). siRNAs are transcribed as long dsR-
NAs that are transported into the cytoplasm 
and cleaved by DICER to yield siRNAs of 
EXCLI Journal 2015;14:714-746 – ISSN 1611-2156 




19 to 24 nucleotides with phosphorylated 5’-
ends and hydroxylated 3’-ends. The cleaved 
RNAs are subsequently incorporated into a 
multiprotein complex named RNA-induced 
silencing complex (RISC). Using the ther-
modynamic stability of the ends as the main 
criteria, the RISC incorporates one of the 
strands known as the guide or antisense 
strand (AS) into the complex; while the other 
strand, known as the passenger or sense 
strand (SS), is discarded and degraded 
(Schwarz et al., 2003). The proteins of the 
RISC facilitate the correct spatial orientation 
of the antisense strand in order to expose the 
seed region (nucleotides 2 to 8 from the 5’ 
end). The seed region is then used by the 
complex to locate mRNAs that have se-
quences that are complementary or partially 
complementary to the seed region. When 
perfectly complementary sequences are lo-
cated the argonaute 2 (AGO2) protein of the 
RISC promotes degradation of the mRNA, 
thus blocking translation. Partial match be-
tween the mRNAs and the seed region cause 
translational repression rather than degrada-
tion of the mRNA. miRNAs are transcribed 
from endogenous mi-RNA genes as primary 
miRNAs (pri-miRNAs) containing 60-70 
nucleotide stem loop structures. These long 
molecules are processed in the nucleus into 
precursory miRNAs (pre-miRNAs) by 
DROSHA/DGCR8 and are thereafter trans-
ported from the nucleus to the cytoplasm by 
exportin 5. In the cytoplasm, pre-miRNAs 
are further cleaved by Dicer to yield a 20-
23bp long mature miRNA. Mature miRNAs 
are loaded into the RISC to elicit translation-
al inhibition with target mRNA degradation 
or sequestration in cytoplasmic P-bodies 
(Bartel, 2004). Unlike siRNAs and shRNAs, 
miRNAs are only partially complementary to 
their target mRNA 3’ UTR region, regulat-
ing their targets via all four AGO proteins 
(AGO1-4). In this case perfect match is not 
necessary for miRNA to function, thus the 
change in the expression of a single RNA 
may affect hundreds of genes (John et al., 
2004). siRNAs and miRNAs can be exoge-
nously incorporated into cells to engage 
RNAi; this principle is the basis for the use 
of small RNAs for therapeutic purposes (El-
bashir et al., 2001a; Martinez et al., 2002). 
By far, the most popular siRNA design mim-
ics natural Dicer cleavage products. These 
products have the so called canonical design 
and comprise a 21 nucleotide guide strand 
antisense and a complementary passenger 
strand annealed to form a siRNA duplex 
with a 19-bp dsRNA stem and 2 nucleotide 
3′ overhangs at both ends (Elbashir et al., 
2001 a, b). The canonical design can be 
modified to make it shorter or truncated. Ex-
amples of these designs include 16-mer siR-
NAs (Chu and Rana, 2008), blunt 19-bp 
siRNAs (Czauderna et al., 2003), asymmet-
rical siRNAs (Sun et al., 2008) and asym-
metric shorter-duplex siRNA (asiRNA) 
(Chang et al., 2009). 
shRNAs are expressed in cells by deliv-
ery of plasmids or through viral or bacterial 
vectors, (Xiang et al., 2006; Lombardo et al., 
2007) and are transcribed in the nucleus 
from an external expression vector bearing a 
short-doubled stranded DNA sequence with 
a hairpin loop by a RNA polymerase II or 
III. The shRNA transcript is then processed 
by DROSHA, a RNAse III endonuclease. 
The resulting pre-shRNA is exported to the 
cytoplasm, where it is processed by Dicer in-
to 21-25 nt small RNAs, and incorporated in-
to RISC were it exerts its action (Yu et al., 
2002). 
The present review focuses on recent ad-
vances relevant to the use of siRNAs as ther-
apeutic tools. In the following sections we 
will first address general challenges associat-
ed with the use of siRNAs as drugs. We will 
also discuss in detail different strategies used 
to improve the pharmaceutical properties of 
therapeutic siRNAs; such as chemical modi-
fications, delivery strategies as well as the 
key elements that should be taken into ac-
count when designing siRNA-based com-
pounds. Finally we will give a brief update 
on preclinical and clinical developmental 
programs highlighting the specific contribu-
tions of each of these programs to the field 
of RNAi therapeutics.  
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Traditional pharmaceuticals or “small 
molecules” typically tackle diseases by tar-
geting proteins. Most small molecules target 
membrane proteins and/or receptors that are 
readily available to bind to these agents. This 
means that a whole range of targets, mostly 
present in the cytoplasm or nucleus of cells, 
are not available for traditional targeting. In 
contrast to small molecules, siRNAs can be 
designed to target virtually any gene; includ-
ing the traditionally “undruggable” targets. 
On the other side, the avenue primed by dis-
coveries in the genetics field in the last dec-
ade has significantly boosted the identifica-
tion of new drug targets for diseases with 
previously unknown subjacent mechanisms. 
Observational human genetic studies have 
significantly contributed to the validation of 
targets for a given condition (Plenge et al., 
2013) facilitating the way for target-directed 
therapeutics that can take advantage of this 
accumulated knowledge.  
RNAi based compounds are chemically 
synthetized and therefore considered New 
Chemical Entities (NCEs) from a regulatory 
standpoint; however some of the characteris-
tic features of these compounds are closer to 
those of New Biological Entities (NBE). One 
of these characteristics is an enormous speci-
ficity for the target against which they are 
designed. The specificity displayed by siR-
NAs to recognize their target enables the de-
sign of compounds to target dysfunctional 
proteins encoded by genes with single point 
mutations in one allele, hence opening a new 
path for the treatment of genetic disorders 
(Martinez et al., 2013). In addition, exoge-
nously administered unmodified siRNAs are 
identical to those synthetized by cell tran-
scription and processing, therefore their 
breakdown products can be incorporated to 
the endogenous pathways of degradation of 
other oligonucleotides. Compared to other 
oligonucleotide based therapeutic options, 
strategies based on RNAi achieve greater ef-
ficacy since a single guide strand can be used 
for several rounds of mRNA cleavage 
providing a beneficial effect at lower con-
centrations (Bertrand et al., 2002). This has 
broad implications in the clinical setting, as 
it would mean less frequent and/or lower 
doses, thus decreasing the risk of unwanted 
side effects. Finally, siRNA-based drug can-
didates are designed using bioinformatic 
tools to select sequences complementary to 
the target mRNA, thereafter algorithms are 
used to select the specific candidates with 
the highest likelihood of efficacy in humans. 
In addition, candidates can usually be de-
signed to cross-react with the homologous 
gene of other animal species ensuring activi-
ty in the animal model that will be used for 
efficacy or toxicology testing. This latter 
characteristic is thought to simplify transla-
tion to humans from animal models.  
Despite the advantages and the great 
therapeutic potential of RNAi-based thera-
pies, translation of siRNAs into therapeutic 
applications has turned out to be a much 
more tedious task than originally thought and 
is still hindered by multiple obstacles. The in 
vivo efficacy of siRNA based agents is de-
pendent on intact siRNAs to reach the cyto-
plasm of their target cell, given the size and 
charge of naked siRNAs this task has 
stemmed more complicated than anticipated 
(Vicentini et al., 2013). The following sec-
tions will go through the specific characteris-
tics that make siRNAs a very attractive class 
of therapeutic agents highlighting the chal-
lenges that need to be addressed in order to 
mainstream their use in the clinical setting.  
 
STABILITY OF RNAi BASED  
THERAPEUTICS:  
CHEMICAL MODIFICATION  
Unmodified oligonucleotides are ex-
tremely sensible to degradation by nucleases. 
Nucleases cleave the phosphodiester bonds 
of nucleic acids and play essential roles in 
diverse cellular processes such as DNA re-
pair, DNA replication and RNA splicing. 
Nucleases are also a fundamental part of the 
defense system of biological organisms 
(Yang, 2011). Nucleases are very abundant 
in biological fluids and tissues; their concen-
tration and type varies among tissues and 
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cellular compartments (Sorrentino, 2010). 
Nuclease activity significantly hampered de-
velopment of RNAi therapeutics during its 
initial years; this drawback was however 
tackled by chemically modifying siRNAs. 
Various chemical modifications have been 
developed in order to increase stability of ol-
igonucleotides; these modifications can be 
used alone or in combination to achieve spe-
cific goals. It should be kept in mind that 
modifications originally applied to other oli-
gonucleotides such as antisense oligonucleo-
tides or aptamers may not be optimal for 
siRNAs as the mechanism of action of these 
oligonucleotides significantly differs. As 
such, chemical modification of siRNAs 
should be rationalized to ensure compatibil-
ity with the RISC machinery. Tolerance for 
chemical modification of a given part of a 
siRNA is dependent on the physical and 
chemical characteristics of the chemical 
groups as well as the position where they are 
located. Ultimately, the activity of modified 
siRNAs needs to be confirmed in a biologi-
cal setting to ensure silencing activity has 
not been lost.  
As mentioned above, modifications of 
the siRNA molecule must be compatible 
with the endogenous RNAi pathways. As a 
general rule, the SS and the 3’-proximal part 
and 3’-overhang of the AS are more amena-
ble to chemical modification; on the contrary 
the 5’ phosphate, the 5’ proximal part and 
central positions of the AS are more sensi-
tive, especially to multiple or bulky modifi-
cations (Bramsen and Kjems, 2013). The 5’-
phosphate group of the guide strand is re-
quired for the binding to AGO2 (Nykanen et 
al., 2001; Wang et al., 2008), in addition, the 
initial interactions between the guide strand 
and target RNA are mediated by the 5’ prox-
imal seed region; therefore modifications of 
these particular regions may interfere with 
activity (Wang et al., 2008).  
Oligonucleotides are synthetized using 
solid phase phosphoroamidite chemistry. As 
such, amidites are incorporated into a grow-
ing chain as building blocks to obtain a full 
length single strand with the adequate length 
and sequence. Two complementary strands 
are thereafter hybridized to yield a siRNA. 
The availability of modified phosphoroam-
idites significantly simplifies chemical modi-
fication of siRNAs, thus most modifications 
can be incorporated without significantly al-
tering the synthesis process.  
There are three groups of modification 
used to improve stability of siRNAs: (1) 
modification of the phosphodiester back-
bone, (2) sugar modifications and (3) modi-
fication of the ribose ring and nucleoside ba-
ses. This review will focus on the modifica-
tion used in compounds in clinical develop-
ment or in compounds that are close to reach 
this goal. 
 
Modification of the phosphodiester  
backbone 
Nucleotides composing RNA and DNA 
are linked to each other by phosphodiester 
linkages. These bonds are negatively charged 
at physiological pH and are easily cleaved by 
endo- and exonucleases. Modification of this 
negatively charged backbone is typically 
used to enhance oligonucleotide resistance 
against nuclease degradation. The most 
widely used phosphate backbone alteration is 
the phosphorothioate (PS) modification in 
which the non-bridging oxygen atom in the 
phosphate backbone is replaced by a sulfur 
atom. The PS modification introduces chiral-
ity to inter-nucleotide linkages, one of the 
stereochemistries provides resistance to nu-
clease-mediated cleavage (Eckstein, 2002). 
Although strategies for selecting the stereo-
chemistry of the PS linkage have been de-
scribed they are usually synthetized as dia-
stereoisomers thus increasing the overall sta-
bility of the molecule (Guga and Stec, 2003). 
In addition, PS linkages are cost effective 
modifications, easily incorporated using 
standard solid-phase oligonucleotide synthe-
sis protocols (Levin, 1999; Sanghvi, 2011). 
This modification is a major component of 
first generation antisense oligonucleotides 
(ASOs) and is present in the all the FDA ap-
proved oligonucleotide drugs, pegabtanib, 
fomivirsen and mipomersen. As such, the 
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change in physical and chemical properties 
that this modification provides when includ-
ed in a molecule, as well as the related toxic-
ities are well characterized (Eckstein, 2014) 
(see safety section of this review). Depend-
ing on the position, PS bonds can affect ac-
tivity; therefore these modifications are usu-
ally combined with other modifications that 
provide additional serum stability in order to 
avoid excessive loss of activity. In addition, 
PS bond lower the melting temperature of 
siRNAs (approximately 0.5 °C per modifica-
tion), thus potentially reducing specificity. 
For these reasons, activity needs to be con-
firmed in a case per case basis (Deleavey et 
al., 2009). An alternative to the PS bond is 
the boranophosphate inter-nucleotide link-
age, which also provides chirality and is 
more nuclease-resistant and less toxic than 
PS (Hall et al., 2004). On the downside, 
boranophosphate-modified siRNAs are not 
easily manufactured and issues with synthe-
sis and industrial scalability have to be over-
come before they can be used on a regular 
basis. Other internucleotide phosphodiester 
linkages include N’ phosphoramidate (NP) 
linkages, phosphoacetate linkages (PACE), 
morpholino phosphoramidates, and peptide 
nucleic acids (PNA). NP linkages are formed 
by substitution of the 3’-OH by 3’-amine 
functionality (Chen et al., 1995). Phosphon-
oacetate (PACE) linkages are formed by 
substituting for the non-bridging oxygen in 
the nucleotide linkage by acetic group; as 
previously seen in the PS linkages, this in-
troduces chirality to the linkage reducing the 
ability of nucleases to break the bond 
(Sheehan et al., 2003). Morpholino phospho-
ramidites are uncharged substitutes of inter-
nucleotide phosphodiester linkages and the 
furanose sugars of nucleic acids (Moulton 
and Jiang, 2009). Peptide Nucleic Acids 
(PNA) have a neutral charge backbone com-
posed of N-(2-aminoethyl)-glycine (Demi-
dov et al., 1994); thus they have a peptide 
backbone instead of the traditional sugar-
phosphate backbone. Backbone modifica-
tions increase stability against nucleases of 
the molecules that carry them; some of them 
also affect the binding affinity, rate of cellu-
lar uptake and biodistribution properties. 
 
Sugar modifications 
Modification of the sugar moiety of nu-
cleotides is widely used with the main pur-
pose of enhancing siRNA nuclease re-
sistance and hybridization properties. Free 
residues of the sugar ring can be modified at 
different positions or even the whole ribose 
ring can be substituted for a different sugar. 
The most frequently modified positions of 
the ribose are the 2’ and 4’. Structural anal-
yses of the silencing complex have revealed 
specific requirements of siRNAs to be able 
to induce gene silencing. These studies indi-
cated that the 2’-OH group of the ribose ring 
is not specifically required for the silencing 
activity. On the other hand, the formation of 
an A-helix between the mRNA and the AS 
strand is strictly required for activity because 
the RISC complex uses the major groove to 
recognize the mRNA-AS-strand duplex. 
Modifications to the 2’-OH of the sugar ring 
do not fall within this category but are on the 
other hand required for the nuclease mediat-
ed breakdown of the oligonucleotide back-
bone (Chiu and Rana, 2003). Accordingly, 
the 2’-OH of the ribose ring has been heavily 
modified with the aim of increasing stability 
without significantly affecting affinity. 2’-O-
methyl (2’-O-Me) and 2’-Fluoro (2’-F) are 
among the most widely used modifications 
of the 2’OH position. Both enhance siRNA 
nuclease resistance and duplex thermo-
stability and are generally well tolerated at 
most positions (Amarzguioui et al., 2003; 
Czauderna et al., 2003; Chiu and Rana, 
2003; Prakash et al., 2005). Both the 2’-O-
Me and the 2’-F are present in the FDA ap-
proved drug pegaptanib thus their effect on 
toxicity is partially characterized (Ng et al., 
2006). 2’-O-Me and 2’F modifications have 
been combined to yield a fully modified 
siRNA with alternate 2’-O-Me and 2’F mod-
ified nucleotides (Allerson et al., 2005). This 
design can yield very potent and stable com-
pounds but has to be thoroughly tested to en-
sure that compounds carrying this pattern of 
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modification maintain their silencing activity 
(Amarzguioui et al., 2003; Chiu and Rana, 
2003). The 2’-O-Methoxyethyl (2’-O-MOE) 
residue can also be introduced into the 2’ po-
sition of the sugar ring. This modification is 
bulky and poorly tolerated in the AS strand 
but is usually well tolerated in the SS strand 
regardless of the position (Prakash et al., 
2005). The most explored modification apart 
from the 2’ position is the 4’ position. In 
fact, the carbon of the 4’ position can be 
bound to the carbon on the 2’ position by a 
methylene bridge generating a conforma-
tionally closed structure known as locked 
nucleotide analogue (LNA). The incorpora-
tion of LNAs into a siRNA results in an in-
crease in the melting temperature of the 
compound and does not necessarily alter the 
A-helix; thus these modifications are in prin-
ciple compatible with RISC activity (Lundin 
et al., 2013). In addition, binding the two 
carbons removes the OH at the 2’ position 
thus decreasing the activity of nucleases and 
therefore increasing biological stability. Tol-
erance to LNA has shown to be position de-
pendent; not all regions of the molecule tol-
erate the incorporation of these analogues. 
As such, incorporation of these analogues to 
the seed region is known to significantly re-
duce their activity (Lundin et al., 2013). Oth-
er modifications that have been introduced 
into the 4’ residue include the 4’-thioribo-
nucleosides (4’-S). The 4’S-modification en-
hances nuclease stability and increases the 
affinity for the target mRNA. As it is the 
case with other modifications, tolerance to 
4’-S modifications is position dependent and 
are better tolerated in the SS then in the AS. 
In addition, these modifications have shown 
to render synergistic effect on stability and 
biodistribution when combined with 2’-O-
Me or 2’-F modifications (Dande et al., 
2006).  
The complete 5-carbon ribose sugar can 
be substituted for another sugar. This is the 
case of 2'-deoxy-2'-fluoro-beta-D-arabinonu-
cleic acid (FANA) modified nucleotides 
which are based on arabinose rather than on 
ribose (Dowler et al., 2006). This modifica-
tion increases potency and stability of candi-
dates and it is well tolerated on the SS as 
well as on the ends of the AS. Another op-
tion are the unlocked nucleic acids (UNAs), 
which are acyclic derivatives of RNA lack-
ing the C2’-C3’ bond of the RNA ribose 
ring. These nucleotides are frequently used 
to introduce flexibility into the oligonucleo-
tide strand. Incorporation of UNA residues 
can reduce duplex Tm by 5-10 °C; as a con-
sequence extensive UNA modification will 
not support standard siRNA strand anneal-
ing.  
 
Modification of nucleoside bases 
The goal pursued when modifying nucle-
oside bases is to increase duplex stability 
while maintaining and improving native base 
pairing recognition and hydrogen bonding. 
These modifications are significantly less 
used than sugar and backbone modifications. 
Examples of nucleobase modifications in-
clude 5-bromo, 5-iodo- substitutions of ura-
cile, 2-thio, 4-thio, dyhydro and pseudoura-
cil. A thorough review of nucleobase modi-
fications is out of the scope of this review 
and can be found in the works of Peacock 
and coworkers (2011) or Bramsen and 
Kjems (2011). 
 
DELIVERY AND BIODISTRIBUTION 
Delivery of siRNA into their target tissue 
and cellular internalization are still major 
challenges that limit full exploitation of 
RNAi therapeutics (Burnett and Rossi, 2012; 
Juliano et al., 2014). siRNAs have a nega-
tively charged backbone and a size of about 
13 kDa; characteristics that limit their ability 
to cross cell membranes thus restricting ac-
cess to their action site. Several strategies 
have been pursued in order to deliver siR-
NAs to different organs and to increase per-
meability of siRNAs across biological barri-
ers. As of today, successful and clinically 
relevant delivery of siRNAs has only been 
achieved to the liver. Strategies used to reach 
the liver include bioconjugation and lipid 
nanoparticles (LNP). Partially successful 
strategies have also been developed for local 
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treatment in areas such as ophthalmology 
and dermatology. Other therapeutic areas 
still need optimization in terms of delivery in 





cally need to reach and exit the circulatory 
system to reach their target organ. Systemic 
administration of compounds is performed 
by means of the enteral or the parenteral 
route. Molecules entering the body through 
the enteral route need to remain stable in the 
adverse conditions of the gastrointestinal 
(GI) tract until absorption takes place. This 
entails resistance to an acidic environment 
and to enzymes present in the GI tract. Mol-
ecules absorbed by the GI lining are thereaf-
ter required to reach the circulatory system 
after crossing the GI epithelium. Entrance 
through the parenteral routes is certainly less 
aggressive than the enteral route but requires 
the compound to be stable in the extracellu-
lar space and in circulation. In addition, mol-
ecules below 60 kDa are rapidly cleared by 
the kidneys; in accordance to this the elimi-
nation half-life of an intravenously (IV) in-
jected unmodified siRNA has been shown to 
be of approximately 6 min (Soutschek et al., 
2004), indicating a rapid clearance from cir-
culation. Therefore, systemic administration 
also requires avoidance of excessive kidney 
clearance in order to increase the amount of 
compound reaching the target organs. Bio-
distribution of systemically administered na-
ked siRNAs does not correlate with the level 
of organ vascularization but is mostly related 
to the type of endothelium lining present in 
the vasculature of the target organ. The liver 
possesses a specialized kind of endothelial 
cells named liver sinusoidal endothelial cells 
that line the capillaries. The endothelium of 
these capillaries has open pores lacking a di-
aphragm and a basal lamina underneath the 
endothelium allowing the passive entrance of 
substances (Wisse, 1970). These particular 
characteristics make the liver an excellent 
target for RNAi based therapeutics.  
Once a given RNAi therapeutic has 
reached its target cell it needs to reach the 
cytoplasm where it can exert its action. The 
main entrance route of oligonucleotides to 
reach the cytoplasm is the use of one of sev-
eral endocytotic pathways. Thereafter, the 
molecule is required to escape from the en-
dosome before the action of enzymes and the 
acidification that takes place during endo-
some maturation degrades the compound 
(Juliano et al., 2014).  
The major route of excretion of naked ol-
igonucleotides is the kidney and to some ex-
tent the liver. As mentioned above siRNAs 
fall below the size threshold for renal filtra-
tion, accordingly, 70 % of an IV injected 
dose of a siRNA is found in the bladder 60 
minutes after administration; most of the re-
maining amount of compound is cleared 
from circulation by the liver (Bartlett et al., 
2007). 
Biodistribution patterns observed follow-
ing systemic administration of RNAi media-
tors indicate that their pharmaceutical prop-
erties need to be improved in order to be of 
value as therapeutic agents. Stability against 
nucleases can somewhat be overcome by 
chemically modifying the molecule. Other 
issues such as reduction of kidney clearance; 
increased uptake by target organs, optimiza-
tion of cellular uptake and endosomal escape 
need however to be addressed by formula-
tion.  
Strategies used for delivery to the liver 
Rozema and coworkers (Rozema et al., 
2007) elegantly demonstrated that the com-
bination of several strategies can yield a very 
effective formulation for delivering siRNAs 
to hepatocytes (Maier, et al., 2013; Nair et 
al., 2014). The components of this formula-
tion consist of an endosmolytic polymer 
composed of butyl and amino vinyl ether 
(PBAVE) reversely modified with carboxy 
dimethylmaleic anhydride (CMD) containing 
PEG and N-acetilgalactosamine (NAG), to-
gether named as dynamic polyconjugate 
(DPC), and a cholesterol conjugated siRNA 
(chol-siRNA). The amphipathic and endos-
molytic polymer used for the DPC is charge-
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masked so that the membrane activity of the 
polymer is only revealed in the acidic envi-
ronment of the endosome. The other essen-
tial component of the DPC is the NAG at-
tached to the masking agent that provides 
hepatocyte targeting via the ASGPR. NAG 
residues have high affinity for the ASGPR 
abundantly present in the plasma membrane 
of hepatocytes. Previous studies indicated 
that biodistribution of siRNAs could be 
greatly improved by conjugating cholesterol 
to the 3’ end of the SS of a siRNA using a 
pyrrolidine linker (Soutschek et al., 2004). 
Cholesterol conjugation provides greater 
binding capacity to serum proteins thus re-
ducing kidney clearance of the siRNA, in 
addition cholesterol conjugation seems to 
improve the uptake of the siRNA by hepato-
cytes in a mechanism partially mediated by 
the low density lipoprotein receptor (LDLr). 
As a consequence, the elimination half-life 
of an intravenously administered siRNA to 
rats increased from 6 to 95 minutes if the 
siRNA was conjugated to cholesterol. Co-
administering the chol-siRNA with the DPC 
formulation increased the efficacy of the 
compound up to 500-fold (Wong et al., 
2012). It should be mentioned that this for-
mulation does not require the DPC to be 
linked to the chol-siRNA making the manu-
facturing process significantly simpler than 
if both elements of the formulation had to be 
covalently linked. In addition, removing the 
constraint of chol-siRNA attachment to the 
DPC has allowed for the use of other DPCs 
composed of different polymers and with 
different targeting agents (Wong et al., 
2012).  
Lipids have been used for decades to im-
prove the penetrance of nucleic acid into 
cells. This feature, together with the ability 
of lipids to spontaneously form vesicles, 
makes them exceptional carriers for oligonu-
cleotides. Studies correlating structural prop-
erties of lipids with specific activities have 
allowed rational design of complex LNPs 
composed of lipids and other constituents in 
order to maximize in vivo delivery (Morris-
sey et al., 2005; Maier et al., 2013). Encap-
sulation of siRNAs within LNPs protects the 
molecules against nuclease degradation and 
enlarges the compound enough to avoid ex-
cessive renal filtration enabling intravenous 
administration. In addition, intravenously 
administered LNPs bind and exchange com-
ponents with serum proteins; this feature can 
be taken advantage of for targeting purposes. 
The nature of the lipid component of LNPs 
significantly affects its properties; and con-
sequently its biodistribution, cellular uptake 
rate and capacity to bind to serum proteins. 
Positively charged lipids facilitate interaction 
with negatively charged cell surfaces but in-
crease systemic clearance whereas neutral li-
pids improve the biodistribution properties 
of the LNPs but are poorly internalized by 
cells. Therefore efforts to produce a rational-
ly designed LNP have yielded particles com-
posed of amphipathic and structural lipids 
whose positive charge is shielded by poly-
ethylen glycol (PEG) conjugated lipids. The 
length of the PEG conjugated lipids has been 
finely tuned to ensure time-dependent disas-
sociation of the PEG moiety from the LNP in 
blood in order to improve the transfection 
properties of the particle once it reaches its 
target cell. As a result of LNP encapsulation 
the serum half-life of a chemically stabilized 
siRNA administered intravenously to mice 
was improved by 8 fold (from 49 min to 6.5 
h) (Morrissey et al., 2005). The interaction of 
some of these LNPs with serum components 
has been thoroughly studied; the results of 
these studies indicate that binding of the 
LNP to apopoliprotein E (ApoE) significant-
ly improves hepatocyte uptake of the LNPs 
via receptors present in the hepatocyte mem-
brane such as the low density lipoprotein re-
ceptor (LDLR). Akinc and coworkers (2010) 
demonstrated that administration of siRNA 
loaded ionizable LNPs to apoE-/- mice signif-
icantly reduced the silencing efficacy of oth-
erwise active siRNA loaded LNPs. These re-
searchers also showed that the requirement 
of an endogenous delivery system such as 
the ApoE mediated hepatocyte uptake can be 
substituted by an exogenous targeting sys-
tem. To demonstrate this phenomenon triva-
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lent NAG residues were linked to the PEG 
moieties that shield the LNP. Administration 
of these exogenously targeted LNPs to apoE-
/- showed a NAG dose-dependent improve-
ment in activity (Akinc et al., 2010) . 
A similar approach has been used by 
Nair and coworkers (2014) to solve delivery 
and uptake of subcutaneously administered 
siRNAs to hepatocytes (Maier et al., 2013). 
Their approach consists in using chemically 
stabilized siRNAs that are conjugated to 
tiantennary NAG (GalNAc3) on the 3’ end 
of the sense strand of the siRNA. Hepatocyte 
targeting is mediated through the affinity of 
the ASGPR for NAG terminated oligosac-
charides. Binding of the compound to the 
ASGPR mediates internalization via clathrin-
coated vesicles; maturation of the endosome 
reduces the pH of the endosome which pro-
motes dissociation of the ligand-receptor 
complex releasing the siRNA. The potency 
and stability yielded by the different chemis-
tries used for these GalNAc3 conjugated 
siRNAs enables subcutaneous administration 
of the drug (Nair et al., 2014). In addition, 
further stabilization of the siRNAs with an 
undisclosed chemical modification pattern 
yielded a second generation platform known 
as enhanced stabilization chemistry (ESC) as 
opposed to the standard template chemistry 
(STC). 
Systemic strategies to deliver siRNAs outside 
the liver. 
Kidney 
Excretion of siRNAs takes place at the 
level of the kidney; IV administered siRNAs 
without a carrier fall below the filtration 
threshold of the kidney and are therefore rap-
idly taken up by the kidney and excreted in 
urine (van de Water et al., 2006). As men-
tioned in the previous section, a strong signal 
is detected in kidney and bladder following 
IV administration of naked siRNAs. Studies 
have shown that this strong signal mainly 
corresponds to breakdown products of the in-
jected compounds (Cheng et al., 2009). As a 
consequence, chemical stabilization of the 
molecule has been used to improve the 
pharmacokinetic properties of siRNAs for 
renal conditions (Thompson et al., 2012; 
Yang et al., 2014). IV administration of blunt 
ended 19-base pair nucleotide siRNA target-
ing p53 with a pattern of alternate 2’-O-Me 
sugar modified nucleosides in both stands 
shows that serum stabilized siRNAs accumu-
late in the kidneys. Following IV administra-
tion, this compound is rapidly cleared from 
systemic circulation most likely due to its 
low affinity for plasma proteins. The highest 
concentration of the compound is thus ob-
served in the kidneys shortly after admin-
istration where it is reabsorbed by the prox-
imal tubule epithelium where the compound 
has a resident time below 24h. This distribu-
tion pattern correlates with the target gene 
knock down profile observed in kidney that 
is detectable already 3-6 h after administra-
tion and persists for less than 48h (Thomp-
son et al., 2012).  
Tumors 
Solid tumors develop their own vascula-
ture in order to cover their need in nutrients 
and oxygen supply. These newly formed 
vessels are product of aberrant angiogenesis 
signals that result in the formation of fenes-
trated and leaky blood vessels (Baluk et al., 
2005). In addition tumors have a poor lym-
phatic drainage. These structural abnormali-
ties cause differential interstitial pressure re-
sulting in accumulation of nanomaterials and 
large molecules within the tumor. This phe-
nomenon, called enhanced permeability and 
retention effect (EPR), has been taken ad-
vantage of for delivering pharmaceuticals to 
solid tumors following intravenous admin-
istration (Seymour, 1992).  
One of the first approaches designed to 
deliver siRNAs to tumors was by means of 
liposomes and LNPs (Judge et al., 2009; Lee 
et al., 2010). Using this approach Bisanz and 
coworkers (2005) showed that intratumorally 
administered liposome encapsulated siRNAs 
targeting ECM-integrin were able to signifi-
cantly reduce the size of bone tumors in a 
mouse xenograft model. Reduction of the 
tumors in bony tissue was accompanied by a 
very significant reduction in the amount of 
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the targeted integrin. However, the dramatic 
decrease in tumor size was only observed 
when the tumor was located in the bone; this 
was not the case for subcutaneous tumors. 
Analysis of target knock-down in the subcu-
taneous tumors indicated that the siRNA had 
a very potent silencing effect, reaching levels 
of almost 100 %. These results point out that 
although the formulation was able to reach 
subcutaneous tumors, knocking down the 
target gene was not an effective mechanism 
to control tumor growth at this site. Similar 
formulations carrying a siRNA designed to 
silence CSN5 were effective in reducing the 
size of hepatic tumors following IV admin-
istration in an orthotopic mouse model of 
hepatocarcinoma (Lee et al., 2011). Clinical 
validation of this approach was performed 
using LNPs loaded with a combination of 
two siRNAs, one targeting Vascular Growth 
Endothelial Factor-A (VEGF-A) and the 
other targeting Kinesin Spindle Protein 
(KSP). This compound, administered as an 
IV infusion every 2 weeks to advanced can-
cer patients with liver involvement, localized 
preferentially to the liver and spleen due to 
the fenestration of the capillaries in these or-
gans. The analysis of the tumors indicated 
that both siRNAs were detected in the tu-
mors with the exception of KSP siRNA that 
was below the LLOQ in one tumor biopsy 
out of twelve. The assessment of efficacy in 
this phase I study was complicated due to the 
heterogeneity of the types of tumors and to 
the small number of patients. 37 patients 
were evaluated for tumor response out of 
which one, suffering from an endometrial 
tumor with multiple hepatic metastases, 
showed a complete response and three others 
had stable disease (Tabernero et al., 2013).  
Vascular endothelium 
Formulations composed of a highly 
charged cationic lipid (AtuFECT01), neutral 
helper lipids, 1% PEG and a 2’-O-methyl 
stabilized siRNA, named lipoplexes, were 
found to differentially deliver their siRNA 
cargo into the endothelial vasculature of sev-
eral organs following IV administration in 
animal models (Santel et al., 2006). The goal 
when developing this formulation was to in-
crease the number of positive charges per 
cationic lipid to allow more efficient binding 
of the siRNA to the lipid. In addition 1 % 
PEG was added in order to decrease the un-
specific toxicity of cationic lipids. Studies 
performed with fluorescently labeled siR-
NAs to analyze the cellular uptake indicated 
that naked compounds, without any transfec-
tion agent, were actively taken up by cells 
when added at very high concentrations 
(10 µM) whereas equivalent intracellular 
concentrations where achieved when the 
formulation was added at siRNA concentra-
tions that were approximately 1000-fold 
lower. Further studies showed that the intra-
cellular distribution of the naked siRNA dif-
fered from that of the formulated siRNA; the 
naked siRNA was trapped in late endoso-
mal/lysosomal vesicles whereas the formu-
lated siRNA showed an enhanced release 
from endosomes reaching the cytoplasm 
(Santel et al., 2006). The rationale behind the 
specific tissue biodistribution of this formu-
lation is not fully elucidated yet. The size of 
the lipoplex, approximately 120 nm, seems 
to enable crossing of the endothelial cell 
membrane but impede crossing through the 
underlying basal membrane. In addition the 
increased positive charge of the lipoplex 
could increase uptake by endothelial cells. It 
should be mentioned that although several of 
the characteristics of the formulation in-
crease the rate of cellular uptake the silenc-
ing efficacy seems to be tissue dependent. As 
such, lipoplex formulations are able to deliv-
er and mediate gene silencing in the endothe-
lia of some tissues i.e lung, liver, heart but 
are not able to so in the endothelia of other 
tissues such as kidney and spleen.   
 
Strategies used for local delivery 
The pharmaceutical properties of siRNA 
based therapeutics designed to have local ac-
tion are different from those required by 
molecules designed for systemic administra-
tion. The stability of locally applied mole-
cules needs to withstand the particular char-
acteristics of its site of action rather than 
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those of serum. Furthermore, reduced stabil-
ity in serum can be considered an advantage 
for local indications in order to reduce unin-
tended systemic side effects that may arise 
due to presence of the compound in systemic 
circulation. Size and other physical proper-
ties of the molecule/carrier system condition 
the entrance and clearance from the local 
site. Because systemic effects are unwanted 
for locally administered products increasing 
the size of the compound with a carrier is not 
usually required for these particular indica-
tions because avoidance of kidney clearance 
is not specifically needed. Size does also 
condition the ability of a given compound to 
enter the target organ. Most locally accessi-
ble tissues such as the skin or the eye are ex-
tremely well protected from external aggres-
sions; this protection usually entails a thick 
physical barrier and different kinds of chem-
ical barriers. Different strategies can be used 
to overcome the above mentioned barriers 
and deliver compounds locally. Physical ap-
proaches to deliver siRNAs across the stra-
tum corneum barrier include microneedles 
(Chong et al., 2013), intradermal injection 
(Leachman et al., 2010), electroporation 
(Nakai et al., 2007), iontophoresis (Kigasawa 
et al., 2010) among others. Modifications of 
the molecule and/or formulation can also en-
able the molecule to penetrate into the re-
quired region and improve cellular uptake.  
Skin 
A combination of dissolvable micronee-
dles and a modified siRNA has been used to 
overcome the stratum corneum of the skin in 
order to improve cellular uptake. This ap-
proach has been used to obtain a proof-of-
concept study on the possibility of silencing 
a gene in the epidermis (Lara et al., 2012). 
CD44 is uniformly expressed throughout the 
five layers of the epidermis and is therefore 
considered an excellent target to obtain a 
proof-of-concept study to assess the efficacy 
of a delivery system to the skin. Previous 
human studies indicated that doses ranging 
between 3-17 mg of an unmodified siRNA 
targeting keratin 6a N171K mutant mRNA 
were required to observe a clinical effect in a 
patient of pachyonychia congenita (Leach-
man et al., 2010). Modification of the mole-
cule (self-delivery technology) and changing 
the delivery mechanism to microneedles al-
lowed dose reductions of 20-100-fold to treat 
an equivalent area (Lara et al., 2012). It 
should be noted that comparisons were made 
between studies that targeted different genes 
and these genes had different pattern of ex-
pression; therefore further studies should be 
performed in order to determine the specific 
differences between the methods of delivery.  
Eye 
Most programs developing siRNAs for 
eye conditions seek modifying gene expres-
sion in the retina. For this purpose siRNAs 
are intravitreally injected, thus administered 
very close to their site of action. In this sce-
nario strategies to improve siRNA design 
have been focused on increasing cellular up-
take and half-life in vitreous humor.  
Self-delivery-rxRNAs (sd-rxRNAs) in-
corporate modifications to the molecule pre-
cisely to achieve the above mentioned goals. 
The specific design of these compounds con-
sist of a 19 nt antisense strand and a shorter 
sense strand (<15 nt); this results in an 
asymmetric duplex that includes a single 
strand tail that is usually phosphorothioated. 
In addition, the strands include stabilizing 
2’-F and 2-’O-Me modifications and a sterol 
conjugate on the SS to improve cellular up-
take (Byrne et al., 2013). Following addition 
of these compounds prepared with a fluores-
cently labeled siRNA to cell cultures without 
transfection reagent indicated that the com-
pounds were readily taken up by cells. These 
compounds were also able to induce target 
knock-down in a series of different cell types 
in vitro. In vivo analysis of their activity in-
dicated that the structure and pattern of mod-
ification of these compounds enables uptake 
by retinal cells and ensures even distribution 
throughout the mouse retina. According to 
these in vivo analyses the diffusion of the 
compound throughout the vitreous humor 
and uptake by the retina is a relatively slow 
process. Analysis of the biodistribution of 
the compound 2-3 h after injection showed 
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that the compound was only present in the 
ganglion cell layer at that time-point and uni-
form staining of the retina was not observed 
until 24h after injection (Byrne et al., 2013). 
The presence of the compound in the mouse 
retina correlated with a target reduction of 
approximately 50 % 2 days after injection; 
the silencing effect diminished over time but 
was still statistically significant 14 days after 
injection.  
A different approach was pursued by 
Ahmed and coworkers (2011); their results 
indicate that, in contrast to those of Byrne 
and coworkers (2013), chemical stabilization 
of the siRNA is sufficient to enable cellular 
uptake and gene silencing via an RNAi me-
diated mechanism in retina. QPI-1007 is a 
19-nt blunt ended siRNA that has alternate 
2’-O-Me modified RNA nucleosides on the 
antisense strand, an L-DNA cytidine nucleo-
tide on the 3’ end and an inverted deoxyaba-
sic moiety on the 5’ end of the sense stand. 
Intravitreal injections in rats of a fluorescent 
siRNA with an equivalent pattern of modifi-
cations to that of QPI-1007 showed that the 
compound was efficiently taken up by cells. 
Five hours after injection approximately 
90 % of retinal cells had incorporated the 
siRNA and the fluorescent signal was detect-
ed for up to 24 h. Further experiments per-
formed with QPI-1007 showed that siRNA 
was detected by “Stem & Loop” qPCR in the 
retina for up to 28 days after injection (Ah-
med et al., 2011). 
The apparent contradiction of the results 
of Byrne et al. (2013) and Ahmed et al. 
(2011) may be rooted in differences in the 
experimental conditions used in their respec-
tive studies. Direct visualization of uptake 
using fluorescently labeled siRNA has been 
widely used for localization studies. Howev-
er, care should be taken when interpreting 
these results as presence of the label does not 
necessarily entail presence of the intact siR-
NA. In addition subcellular localization is 
not always visualized when using labeled 
siRNAs, therefore additional measures 
should be taken to complement these anal-
yses. Furthermore, the dose administered and 
timing of tissue collection are crucial factors 
for determining the extent of tissue distribu-
tion. On top of this, the pattern of modifica-
tion of the molecule as well as the half-life 
and abundance of the targeted mRNA may 
have a direct influence on the kinetics of the 
subsequent processes leading to gene silenc-
ing; therefore care should be taken when ex-
trapolating results obtained with one mole-
cule to other siRNAs.  
 
EFFICACY 
Gene-silencing efficacy varies signifi-
cantly depending on the target gene and spe-
cific sequence chosen (Holen et al., 2002). 
Factors influencing the efficacy of a particu-
lar approach may be related to the biology of 
the gene or related to the design of the siR-
NA. Information on the abundance and half-
life of a given mRNA as well as the turnover 
rate of the corresponding protein influences 
target selection. mRNAs with a higher turn-
over are usually more resistant to be silenced 
than those with a lower turnover; the same 
holds true for the stability of the protein 
(Larsson et al., 2010). Methods for identify-
ing active siRNA sequences have signifi-
cantly evolved leading to the development of 
algorithms that now include analysis of po-
tential secondary structures, predictions of 
thermodynamic stability, analysis of base 
composition and presence or absence of spe-
cific motifs. The correlation between the GC 
content and siRNA potency has been ad-
dressed by several research groups (Reyn-
olds et al., 2004; Patel et al., 2006; Pei and 
Tuschl, 2006). The results of these studies 
have shown that a high GC content may be a 
negative determinant of the functionality of a 
siRNA as it may inhibit the dissociation of 
the duplex impairing RISC loading. On the 
other hand, low GC content is associated 
with a decrease in potency, presumably due 
to decreased target affinity and specificity 
(Pei and Tuschl, 2006). Recent studies have 
shown that siRNA sequences with a GC con-
tent in the range of 25-55 % have an in-
creased potency (Liu et al., 2012). Inclusion 
or absence of certain motifs has also found to 
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have an impact on siRNA potency; as such 
the following motifs (5’ to 3’) “CUU”, 
“CU”, “UCU” and “GUU” have been found 
to have a positive effect on potency. The ef-
fect of the “UCU” motif seems to be particu-
larly effective when positioned at the end of 
the guide strand (Klingelhoefer et al., 2009). 
On the other hand, the motif “CCG” report-
edly increases siRNA potency when placed 
at NT4-6, NT14-16 and NT16-18 (Liu et al., 
2012). Other motifs seem to negatively cor-
relate with potency; an example of this in the 
tetranucleotide motif “ACGA”. The thermo-
dynamic properties have also a critical role 
in siRNA design, thus siRNA with high po-
tency tend to have guide strands with less 
stable 5’-ends than their 3’ end (Reynolds et 
al., 2004). Finally, there is a negative corre-
lation between the self-folding tendency of a 
given siRNA and its potency, as the presence 
of secondary structures may affect the inter-
action between the guide strand and its target 
(Klingelhoefer et al., 2009; Liu et al., 2012)  
 
SAFETY 
siRNAs are chemically synthetized mol-
ecules that frequently contain chemical mod-
ifications that do not necessarily occur natu-
rally in biological organisms. As mentioned 
previously, siRNAs are regulated as NCEs. 
However, the mechanism of action these 
molecules entails using a biological path to 
exert their action; hence siRNAs have some 
attributes in common with NBEs. The toxici-
ties observed in response to siRNAs can thus 
arise as a consequence of their particular 
chemistry and/or the chemistry of their de-
livery vehicle but can also be due to activa-
tion of intended or unintended biological 
pathways (Black et al., 1994; Levin and 
Henry, 2008).  
Taking into account the above, toxicities 
associated to siRNAs are usually classified 
into one of two categories a) hybridization 
dependent toxicities and b) hybridization in-
dependent toxicities. Hybridization depend-
ent toxicities arise from the interaction of 
siRNAs with other oligonucleotides through 
Watson and Crick base-pairing. Hybridiza-
tion independent toxicities of siRNAs are not 
related to base-pairing (Lindow et al., 2012) 
and are typically sub classified into toxicities 
associated to chemical modifications, to de-
livery agents or to immunomodulation. In 
addition, siRNAs can cause toxic phenotypes 
associated to the appropriation of the RNAi 
machinery, which is required for normal cell 
function. Table 1 summarizes the classifica-
tion of toxicities according to their origin 
and the strategies recommended by the Oli-
gonucleotide Safety Working Group 
(OSWG) to manage and test the relevance of 
these toxicities (Lindow et al., 2012; Korn-
brust et al., 2013; Berman et al., 2014). 
Toxicities due to base-pairing can be due 
to exaggerated pharmacology (EP) or off-
target effects (OTEs). The former is caused 
by inhibition of the targeted gene to an ex-
tent that causes deleterious effects; the latter 
are caused by direct or indirect modulation 
of genes that are not intentionally targeted.  
 
Hybridization dependent toxicities 
Off-target-effects (OTEs) 
siRNAs can modulate unintended genes 
by an RNAi mechanism, induced by the SS 
or the AS, or by miRNA-like effects (Bir-
mingham et al., 2006; Jackson et al., 2006). 
The hybridization properties of siRNAs 
based of predictable binding to other RNA 
sequences enable the implementation of al-
gorithms directed towards the reduction of 
off-targets. In addition certain chemical 
modifications of the molecule can signifi-
cantly reduce the number of unintended tar-
gets. As such, Jackson and colleagues (2006) 
found that placing a 2’-O-Me group on the 
second position of the guide strand inhibited 
off target silencing due to complementarity 
to the seed region without significantly af-
fecting the silencing efficacy. Other options 
to reduce OTEs are selective placement of 
LNA residues (Puri et al., 2008) or incorpo-
ration of UNA residues at position 7 of the 
5’-end of the passenger strand (Bramsen et 
al., 2010). These modifications block the in-
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Table 1: Classification of toxicities of siRNA-based compounds and recommendations to assess 
eventual toxicities 
Hybridization dependent Non hybridization dependent 
Toxicity Management Toxicity Management 
Off target effects  Adequate in silico  
design 
 Interpretation of in silico 
hits with auxiliary data 




 Assess eventual  




 Evaluate using a least 
one relevant animal 
species. 
 Evaluate the use of an 
animal analogue 
 Draw careful  
conclusions from animal 
analogues 
Delivery system  
related 
 No formal recommen-
dations 




corporation of the sense strand to the RISC 
impairing potential OTEs mediated by the 
sense strand. In addition, these modifications 
contribute to improving the pharmaceutical 
properties of the duplexes by increasing their 
stability (Sioud, 2015). As general rule, 
modifications that block the ability of the 
passenger strand to enter and induce RISC 
mediated silencing as well as modifications 
that block the phosphorylation of the 5’ end 
of the SS such as 5’-O-methylation reduce 
the likelihood of OTEs (Vaish et al., 2011). 
Predictability of affecting unintended targets 
does not necessarily warrant that the chosen 
sequence does not have OTEs but enables 
reduction and identification of these hypo-
thetically modulated genes. Following the 
identification of a potential OTEs, the rele-
vance of the alleged off-target can be as-
sessed by complementing the in silico data 
with relevant biological data such as effect of 
genetic deletions, pharmacological modula-
tion or pattern of expression in relevant tis-
sues. Thereafter in vitro and in vivo experi-
ments can be set up in order to evaluate the 
relevance of the potential off-target for the 
specific therapeutic purpose of the molecule.  
Exaggerated Pharmacology (EP) 
Modulation of gene expression by siR-
NAs can very efficiently change the disease 
state but if the pharmacological effect is 
greater than desired the very advantages of 
this drug class can be responsible for causing 
deleterious effects. In the RNAi field the ex-
tent and relevance of exaggerated pharma-
cology is dependent on the selected target 
gene. As such, exaggerated pharmacology is 
completely irrelevant for compounds target-
ing exogenous sequences such as viral genes; 
but can be relevant when targeting host 
genes. Relevance of EP should be addressed 
taking into account available data for the tar-
get gene: pattern of expression, biological 
consequences of deletion and/or modulation 
using genetic or pharmacologic tools and 
specific elements of the developmental pro-
gram and selected candidate such as potency, 
administration route, dosing frequency and 
acceptable levels of toxicity (Kornbrust et 
al., 2013). In addition knowledge of the dis-
tribution of the compound should contribute 
to investigating the relevance of exaggerated 
pharmacology. Strategies to restrict access of 
a given compound to organs were the action 
of the compound is not intended can be de-
veloped in order to diminish the off-site 
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pharmacological effect. Administration of 
naked compounds to the eye is one example 
of these kind of strategies as it restricts the 
activity of the molecule to the intended or-
gan by ensuring degradation when the com-
pound reaches systemic circulation (Mar-
tinez et al., 2014). Other examples of modu-
lating biodistribution to reduce unintended 
pharmacological effects include targeted- de-
livery strategies to preferentially direct a 
compound to the intended organ; thus avoid-
ing long residence time in other organs.  
 
Hybridization dependent toxicities 
Toxicity related to chemical modifications or 
to the delivery vehicle  
Most of the toxicities related to siRNAs 
are linked to either its chemistry or to the 
characteristics of the delivery vehicle (Levin 
and Henry, 2008). Modifications have be-
come a common tool to increase half-life of 
siRNAs in biological fluids, to reduce their 
immunostimulatory properties and to im-
prove other pharmacological characteristics 
of siRNA such as distribution, specificity 
and activity but it should be kept in mind 
that modifications affect both the efficacy 
and toxicity of the molecule. Most chemical 
modifications incorporated into siRNAs have 
been adopted from observations made with 
“their older brothers” antisense oligonucleo-
tides. The relevance of these modifications 
when introduced to siRNAs is not necessari-
ly applicable to siRNAs as dosing regimens 
and plasma/tissue concentration may be sig-
nificantly different from those of ASOs. The 
following section summarizes the toxicities 
associated to those modifications that have 
been introduced to siRNAs that are currently 
advancing through clinical trials and of 
which some experience has been accumulat-
ed.  
As seen in previous section “Modifica-
tion of the phosphodiester backbone”, back-
bone modifications are widely used to reduce 
nuclease activity; the most commonly used 
of these modifications is the replacement of 
a non-bridging oxygen on the backbone be-
tween two ribonucleotides with a sulphur to 
create a PS linkage. This modification not 
only enhances stability but also increases 
cellular uptake (Eckstein, 2014). Phospho-
phorotioated oligonucleotides are stickier 
than non phosphorothioated versions and 
tend to strongly bind to proteins. Upon syste-
mic administration, phosphorothioated oligo-
nucleotides bind to plasma proteins increas-
ing the mean half-life approximately 10 
times (Eckstein, 2014). Due to this ability to 
interact with plasma proteins phosphorothio-
ated oligonucleotides are able to dose-depen-
dently activate the complement cascade via 
the alternative pathway (Galbraith et al., 
1994). Activation of the complement cascade 
leads to acute hematologic and hemodynam-
ic disturbances that can potentially be life-
threatening (Henry et al., 2002). These ob-
servations, made with ASOs, are dose-
dependent and can be managed by slowing 
down the infusion rates thus keeping the 
phosphorotioated oligonucleotide concentra-
tions below the threshold for complement ac-
tivation (Henry et al., 1997). Phosphorothio-
ated siRNAs can thus potentially also acti-
vate the complement cascade but because the 
concentration required for therapeutic pur-
poses is in most cases significantly lower 
than that of ASOs the likelihood of these 
side-effect is reduced. Assessment of phos-
phorothioate-associated toxicities in pro-
grams developing a siRNA that reaches sys-
temic circulation should therefore include 
measurement of split-products of resulting 
from complement activation such as C3a, 
C5a and Bb and assessment of blood pres-
sure and electrocardiogram in toxicity stud-
ies and transient inhibitions of the clotting 
cascade due to secondary activation of neu-
trophils in non-human primates (NHP) (Hen-
ry et al., 2014).   
LNAs are formed by linking 2’ and 4’ 
carbons of the ribose ring by a methylene 
bridge (Koshkin and Wengel, 1998). The 
bridge between the two carbons constrains 
the ribose ring rendering a structure close to 
that of RNA after hybridization. The con-
straining of the ribose increases the melting 
temperature of the oligonucleotide 2-8 °C 
EXCLI Journal 2015;14:714-746 – ISSN 1611-2156 




per LNA nucleotide incorporated; thus en-
hancing the affinity of LNA oligonucleotides 
for complementary sequences. LNA-con-
taining RNA duplexes are hence stabilized 
against nucleases (Stein et al., 2010). In ad-
dition, incorporation of LNA nucleotides 
improves activity and specificity by ensuring 
preferential loading of the antisense strand 
into the RISC (Elmen et al., 2005) and may 
reduce immunogenicity (Goodchild et al., 
2009). However, introduction of these modi-
fications in certain trinucleotide sequence 
motifs can increase hepatotoxicity of LNA-
bearing oligonucleotides. The mechanism by 
which LNA-ASOs induce hepatotoxicity is 
not fully elucidated yet but could be initiated 
by the ability of these motifs to bind to hepa-
tocellular proteins and mediated by activa-
tion of stress pathways (Burdick et al., 
2014).  
Chemical substitution at the 2’-hydroxyl 
group of the sugar moiety 2’-O-Me, 2’-F or 
2’-MOE are extensively used to improve 
stability and reduce immunogenicity. These 
modifications increase the melting tempera-
ture of the oligonucleotide carrying them 
rendering more stable molecules and reduce 
immunostimulatory effects (Chiu and Rana, 
2003). The breakdown of products contain-
ing modified nucleotides renders however 
non-naturally occurring mononucleotides. 
These non-naturally occurring mononucleo-
tides can potentially be incorporated into nu-
cleotide pools and be reused for synthesis of 
other macromolecules. Incorporation of these 
modified nucleotides to newly synthetized 
DNA could potentially lead to genotoxicity. 
In addition, it is well known that certain base 
analogues such as fialuridine (FIAU) can 
cause multisystem failure due to mitochon-
drial damage (McKenzie et al., 1995). In 
humans FIAU is transported into the mito-
chondria by the human equilibrative nucleo-
side transporter 1 (hENT1) and thereafter is 
metabolized by the thymidine kinase 2 to 
yield FIAU-triphosphate (FIAU-TP). FIAU-
TP is a potent inhibitor of mitochondrial 
DNA polymerase-γ, thus causes depletion of 
mitochondrial DNA and cell death (Colacino 
et al., 1996; Lewis et al., 1996). It should be 
noted that the mouse equivalent to hENT1 is 
not expressed in mouse liver; therefore 
woodchucks have traditionally been used to 
assess toxicities similar to that of FIAU (Lee 
et al., 2006). Other analogues, currently used 
as antivirals for treatment of HIV, act as 
chain terminators to suppress viral replica-
tion as they lack a 3’-OH (Johnson et al., 
2001). These analogues can also act as sub-
strates for the mitochondrial DNA polymer-
ase-γ resulting in inhibition of mitochondrial 
replication. The results of several programs 
developing modified oligonucleotides for 
therapeutic purposes have shown that modi-
fications studied up to date do not alter nu-
cleotide pools nor are they genotoxic (Levin 
and Henry, 2008). In the case of phos-
phorothioated oligonucleotides the European 
Medicines Agency specifically used availa-
ble data up to 2005 to publish a reflection 
paper indicating that assessing the mutagenic 
potential of phosphorothioated oligonucleo-
tides is not necessary (European Medicines 
Agency, 2005).  
Finally, compounds using lipid based ve-
hicles such as LNPs can cause infusion-
related reactions, elevation of cytokines and 
activation of the complement cascade (Bar-
ros and Gollob, 2012). Studies with several 
compounds using different types and compo-
sition of LNPs have shown different degree 
of infusion reactions; these reactions were 
particularly relevant when using first genera-
tion LNPs; newer versions of LNPs induce a 
lower immunogenic response. Infusion reac-
tions are in general controlled by decreasing 
the infusion rate but in some cases pretreat-
ment with dexamethasone and/or antihista-
mines is required (Tabernero et al., 2013). 
Immunomodulation 
Cells have the ability to defend them-
selves against the entrance of exogenous ge-
netic material. This essential function in de-
fense against infection becomes a hurdle try-
ing to artificially introduce an oligonucleo-
tide for therapeutic purposes. The recogni-
tion of foreign DNA or RNA by the innate 
immune system induces the production of 
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type I interferon and pro-inflammatory cyto-
kines. The innate immune has the ability of 
recognizing pathogen associated material by 
means of germ-line pattern recognitions re-
ceptors (PPR) that promote rapid responses 
to microbial pathogens during the invading 
phase. These receptors recognize conserved 
pathogen–associated molecular patterns 
(PAMPs) which are not present in the host 
and are usually important for pathogenicity 
and/or survival of the pathogens (Parkin and 
Cohen, 2001). PAMPs are unique to micro-
organisms and can be of different nature in-
cluding lipopolysaccharides, peptidoglycans, 
capsular structures, bacterial flagellins, bac-
terial DNA, lipids, viral RNAs and glycopro-
teins. There are several proteins that special-
ize in recognizing PAMPS, focus in this re-
view will be put on those proteins specializ-
ing in sensing genetic material. Proteins spe-
cialized in recognizing genetic material are 
present in the cytosol, and use different 
mechanisms to sense potentially pathogenic 
genetic material and mediate an aggressive 
response that generally leads to cell death. 
These enzymes include dsRNA-dependent 
protein kinase (PKR), 2-5 oligoadenylate 
synthetase (OAS), retinoic acid inducible 
gene (RIG-1) and melanoma differentiation-
associated gene 5 (MDA-5). PKR phosphor-
ylates serine and threonine residues of spe-
cific proteins following activation upon rec-
ognizing and binding to dsRNA. The PKR-
induced phosphorylation of a certain subset 
of proteins leads to translation arrest and ul-
timately to apoptosis (Meurs et al., 1990). 2-
5-oligoadenylate synthetase (OAS) is upreg-
ulated in response to long dsRNA and type I 
interferon. Activation of this enzyme results 
in formation of 2’-to 5’-linked oligoad-
enilates that subsequently activates RNAse 
L; enzyme that degrades cellular and viral 
RNAs (Samuel, 2001). RIG-1 encodes a 
multimeric protein with two caspase recruit-
ing domains (CARD) and a helicase domain. 
The helicase domain of the protein has the 
ability to bind to ss-RNA or ds-RNA. Upon 
binding, RIG-1 suffers a conformational 
change that allows the CARDs to interact 
with another CARD-containing protein 
named as IPS-1. IPS-1 is in turn responsible 
for the activation of IRF3 that results in an 
increase in the production of interferon β and 
inflammatory mediators and activation of 
programmed cell death program of the cell 
(Marques and Williams, 2005; Marques et 
al., 2006). MDA-5 is structurally similar to 
RIG-1 but undergoes a different molecular 
pathway to activation probably triggered by 
a different subset of virus than that of RIG-1 
(Kato et al., 2006; Zheng et al., 2015).  
Toll Like Receptors (TLRs) are mainly 
expressed in immune cells and are crucial for 
detection of pathogen-derived products and 
activation of immunity (Takeda and Akira, 
2005; Sioud, 2006a). TLRs are present in the 
cell plasma membrane where they sense ex-
ternal PAMPs or in the intracellular com-
partments where they detect foreign nucleic 
acids resulting from the degradation of path-
ogens within the endocytic compartments. 
TLR3, TLR7, TLR8 and TLR9 sense nucleic 
acids; TLR7 and TLR8 recognize ssRNA 
rich in guanosine and uridine (Hornung et 
al., 2008). Activation of TLR8 seems to be 
more sequence specific whereas it is thought 
that a ribose backbone and multiple uridines 
are required for activation of TLR7 (Judge et 
al., 2005; Diebold et al., 2006). It should be 
noted that although mice express TLR8 this 
receptor is not activated by the same stimuli 
as it is in humans and should therefore be 
taking into account when assaying the im-
munostimaltion properties of siRNAs in pre-
clinical developmental programs. TLR3 rec-
ognizes dsRNA and is present in intracellular 
compartments of mature dendritic cells and a 
whole wide range of non-immune cell types 
including epithelial, endothelial and fibro-
blast lines. siRNAs of 21 nucleotides or 
more activate this receptor inducing a cyto-
kine response mainly composed of INFγ and 
IL-12 (Kleinman et al., 2008).  
Several strategies have been developed to 
enable synthetic siRNAs evading detection 
by the innate immune system. These strate-
gies include design rules, chemical modifica-
tions and formulation in carriers to avoid de-
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livering naked siRNAs into endosomes. A 
wide variety of chemical modifications that, 
as discussed in section “Stability of RNAi 
based therapeutics: chemical modification” 
confer nuclease resistance have been suc-
cessfully used to abrogate siRNA immune 
activation. Morrisey and colleagues showed 
that the incorporation of 2’ modified nucleo-
tides such as, DNA bases, 2’-O-Me purines, 
2’F pyrimidines, terminal inverted-dT bases, 
and PS linkage at selected positions can ab-
rogate siRNA immune activation (Sioud, 
2006b). As mentioned previously, chemical 
modification of the molecule regardless of 
the final aim should be handled with care in 
order to avoid loss of silencing activity. Re-
placement of uridines with their 2´Fluoro, 
2’-deoxy or 2’-O-Me modified counterparts 
can block TLR recognition without signifi-
cantly reducing the silencing potency (Sioud, 
2006b). The same holds true for the re-
placement of uridines for thymidines in the 
sense strand (Flatekval and Sioud, 2009). 
Ideally, in vitro studies should be performed 
using a mixed population of primary immune 
cells such as fresh peripheral blood mononu-
clear cells to test immunogenicity in vitro, 
but most importantly, signs of immune acti-
vation should be monitored in vivo by exam-
ining cytokine levels and activation of in-
flammatory pathway genes at a short time-
point and 24 hours after administration 
(Coch et al., 2013). 
 
PROGRAMS IN CLINICAL  
DEVELOPMENT 
With two compounds in phase III and 
several compounds in advanced phase II the 
RNAi filed is certainly getting closer to the 
market. Table 2 summarizes the current sta-
tus of clinical candidates and the characteris-
tics of each compound.  
 
Table 2: Programs in clinical development. (A) Active, (C) Complete and (T) Terminated 
Clinical  









TransDerm Phase I (C) 
















STC-GalNac-SQ Alnylam  Phase III (A) 
ALN-PCS02 Hypercholesterol-
emia 
PCSK9 LNP-IV Alnylam  Phase I (A) 
ALN-PCSsc Hypercholesterol-
emia 
PCSK9 GalNac-SQ Alnylam/The Med-
icines Company 
Phase I (A) 
TKM-ApoB Hypercholesterol-
emia 
APOB LNP-IV Tekmira  Phase I (T) 
ND L02-
s0201 
Liver fibrosis HSP47 VitA conj. LNP-IV Nitto Denko Phase Ib/II 
(A) 





























Phase IIa (A) 
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setting Drug Indication(s) Target(s) Delivery Sponsor Status 
PF-04523655 AMD with cho-
roidal neovascu-
larization 
RTP801 Naked-IVT Quark/Pfizer Phase II (C) 
Diabetic macular 
oedema 
Phase IIb (A) 
SYL040012 
(Bamosiran) 
Glaucoma β2 ADR Naked-Eye drop Sylentis Phase IIb (A) 
SYL1001 Ocular pain asso-
ciated to dry eye 
disease 
TRPV1 Naked-Eye drop Sylentis Phase Ib/IIa 
(A) 
Cancer TKM-PLK1 Solid tumours or 
lymphoma 
PLK1 LNP-IV Tekmira  Phase I/II (A) 
Hepatocellular 
carcinoma 
Phase I/II (A) 
CALAA-01 Solid tumours RRM2 NP-IV Calando Pharm. Phase Ib (T) 
ALN-VSP02 Liver cancer and 




LNP-IV Alnylam Phase I (C) 
Atu027 Advanced, recur-
rent or metastatic 
solid malignan-
cies 








EphA2 Liposomes-IV M.D. Anderson 
Cancer Center 

















lar surgery  
P53 Naked-IV Quark Pharm., 
Inc./Novartis 




Phase II (A) 
Kidney injury 
acute renal failure
Phase I (C) 
Viral  
Infections 
TKM-Ebola Ebola Viral RNA (pol, 
VP24, VP35) 
LNP-IV Tekmira Pharm. Phase I (A) 





Naked-IN Alnylam Pharm. Phase IIb (C) 
ARC-520 Chronic hepatitis 
B 




Phase II (A) 
TT-034 Hepatitis C HCV DNA dRNAi –based 
multi-cassette 
vector, IV 
Benitec Phase I/II (A) 
 
 
Products using systemic administration 
Targeting the liver 
Transthyretin amyloidosis 
Patisiran (ALN-TTR02) targets transthy-
retin (TTR) and is the most advanced candi-
date in the RNAi pipeline (phase III) (Coel-
ho et al., 2013). This compound, being de-
veloped for the treatment of familial amyloi-
dotic polyneuropathy (FAP), obtained or-
phan drug status in US/EU and fast track 
designation by the FDA. FAP is an autoso-
mal dominant condition caused by mutations 
to the TTR gene. FAP causing mutations in 
the TTR gene yield defective proteins that 
fail multimerize to form the functional te-
tramer and instead self-assemble into amy-
loid fibrils that subsequently accumulate in 
different organs (Hou et al., 2007). Most in-
dividuals carrying mutations in the TTR 
gene are heterozygous; thus accumulations 
found in tissues of affected individuals con-
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tain both mutant and non-mutant protein. 
Accumulation of liver derived TTR in the 
peripheral nervous system is thought to be 
the primary cause of FAP although the neu-
rotoxic mechanism induced by TTR accumu-
lation is poorly understood. TTR is present 
in plasma and cerebrospinal fluid where it is 
involved in the transportation of thyroxine 
and retinol but the role of this protein does 
not seem to be essential for life. As such, re-
duction of TTR appears to be a valid ap-
proach to treat the disease. Patisiran is a 
siRNA designed to silence non-mutant and 
mutant TTR encapsulated in a LNP formula-
tion. Human trials for this compound have 
shown a robust, dose-dependent and durable 
reduction of the targeted protein in serum in 
response to single and repeated doses of the 
compound (Coelho et al., 2013). Six-month 
clinical data of a phase II extension study in 
which patients received infusions of 
0.3 mg/kg every three weeks were recently 
presented and indicated that the compound 
possibly stabilizes disease progression. The 
main side-effects observed in response to 
patisiran were infusion-site reaction (14.8 %) 
and flushing (14.8 %) most likely caused by 
the delivery vehicle. 
Revusiran (ALN-TTRsc) is an adaptation 
of patisiran into the new NAC-based deliv-
ery platform. This compound is currently in 
phase II for another type of TTR-amyloido-
sis: familial amyloidotic cardiopathy (FAC). 
In this type of amyloidosis cardiac amyloid 
deposition leads to cardiac wall thickening 
and heart failure (Hermansen et al., 1995). 
The change in delivery method of this com-
pound allows subcutaneous administration 
which also requires change of dose regimen. 
In the ongoing phase 2 study daily doses of 5 
or 7.5 mg/kg are given during an initial load-
ing period of 5 days and thereafter weekly 
doses are administered until the end of the 
study. The main side effects observed up to 
date in response to revusiran are injection 
site erythema (23 %) and transient elevation 
of liver function tests (15 %). The maximum 
serum TTR knock-down observed in this 
study up to date is 98.2 % with a mean max-
imum knockdown of 87 %.  
Cardio-Metabolic diseases 
ALN-PCS02 is a LNP formulated siRNA 
targeting proprotein convertase subtil-
isin/kexin type 9 (PCSK9), a key protein in 
the regulation of cholesterol homeostasis. 
PCSK9 enhances degradation of hepatic 
LDLR, thus resulting reduced hepatic LDL-
cholesterol clearance. Loss of function muta-
tions in PCSK9 have been described in hu-
mans and are associated with reduced LDL 
cholesterol and coronary heart disease (Co-
hen et al., 2006). A phase 1 trial was per-
formed with ALN-PCS02 in subjects with 
cholesterol levels above 3.00 mmol/L. The 
results of this trial showed that a single dose 
of IV infused ALN-PCS02 was well tolerat-
ed and the highest doses tested caused a sig-
nificant reduction in plasma PCSK9 and se-
rum LDL-cholesterol. Patients in this trial 
were pretreated with immunosuppressants 
and antihistamines to avoid a potential im-
mune stimulation response associated with 
LNP based delivery vehicles (Fitzgerald et 
al., 2013). Further development of this pro-
gram will be performed with ALN-PCSsc, a 
compound co-developed by Alnylam and the 
Medicines Company that entails a change in-
to the NAC-based delivery platform and thus 
subcutaneous (SQ) dosing. A phase I study 
has recently been initiated for this compound 
with the goal of assessing safety and tolera-
bility of single ascending doses as well as 
multiple dosing in patients with elevated 
baseline LDL-C. This compound also incor-
porates improvements to the NAC-based 
technology that are the basis for the ESC-
technology (Nair et al., 2014). 
TMK-ApoB was one of the first com-
pounds based on RNAi to reach clinical tri-
als. The program, terminated in 2010, used a 
siRNA targeting Apoliprotein B (ApoB) en-
capsulated in first generation LNPs. The 
phase I clinical trial was halted due to unex-
pected immune stimulation. The preclinical 
evaluation of this product had not anticipated 
the subsequent events observed in the phase 
I trial thus raising the question whether pre-
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clinical models were good predictors of the 
immune response. Much has been learnt 
since the mentioned trial and new formula-
tions have been designed in order to reduce 
the immunostimulatory properties of LNPs; 
this has been partially achieved by modify-
ing the composition of LNP as well by re-
ducing the infusion rates while administering 
the compound (Coelho et al., 2013). In addi-
tion mechanistic studies have shed light on 
the underlying causes for the LNP-induced 
immune stimulation and more importantly 
the failure in preclinical models to anticipate 
the mentioned toxicities (Coch et al., 2013).  
Liver cirrhosis and fibrotic disease of the 
liver 
ND L02-s0201 is a siRNA targeting Heat 
Shock Protein 47 (HSP47) formulated in vit-
amin A-conjugated LNPs under development 
by Nitto Denko for the treatment of fibrotic 
diseases of the liver (Sato et al., 2008). 
HSP47 is an endoplasmic reticulum chaper-
one specific for the correct folding and stabi-
lization of procollagen (Nagata, 1996). Inhi-
bition of this chaperone impairs collagen 
maturation and has been shown to be benefi-
cial in liver fibrosis (Arthur, 2002). The vit-
amin A moiety provides receptor mediated 
targeting to hepatic stellar cells by the affini-
ty of vitamin A for retinol binding protein. 
This product is currently undergoing phase 
Ib/II clinical trials in patients with moderate 
to extensive liver fibrosis that are receiving 
either a once a week or a twice a week IV 
dosing of the compound.  
Cancer 
TKM-PKL1 is a LNP formulated RNAi 
trigger that targets polo kinase 1 (PLK1). 
PLKs are a family of proteins with important 
roles in cell cycle regulation. PLK1 can 
override certain regulation points in the cell 
cycle causing genetic instability and promot-
ing tumor development (Strebhardt and 
Ullrich, 2006). One phase I trial for primary 
or secondary liver cancer has been complet-
ed for this compound and two phase 1/2 tri-
als, one for hepatocellular carcinoma and the 
other for neuroendocrine tumors, are current-
ly ongoing. TKM-PLK1 is formulated in 
first generation LNPs and is therefore able to 
induce immunogenic responses. Cytokine re-
lease symptoms occurred at the limit-dose of 
0.9 mg/Kg, dose at which 25% of the pa-
tients showed elevations 6 h after infusion. 
This elevation in cytokines required addi-
tional immunosuppression (dexamethasone 
and diphenhydramine 3 hours after dosing) 
on top of the pre-dose immunosuppression.  
Atu027 is Silence Therapeutic’s clinical 
candidate for cancer. The product is a modi-
fied siRNA targeting Protein Kinase N3 
(PKN3) formulated in lipoplex nanoparti-
cles. The particular lipid composition of the 
formulation facilitates delivery to the vascu-
lar endothelium. PKN3 is a downstream ef-
fector of phosphatidylinositol 3-kinase 
(PI3K), a kinase that controls a transduction 
pathway commonly dysregulated in several 
forms of cancer. Silencing PKN3 stabilizes 
the vasculature and attenuates inflammatory 
responses in tumors reducing vasculature 
leakage and permeability; as a consequence 
there is a reduction in extravasation of meta-
static cells and a reduction in the number of 
metastases in animal models (Santel et al., 
2006). A phase I dose escalating study was 
performed with this drug in patients with dif-
ferent types of solid tumors; the results of 
this study showed that the drug was well tol-
erated and disease stabilization over a period 
of 8 weeks was observed in 41 % of the pa-
tients.  
Kidney disorders 
Initial biodistribution studies showed that 
systemically administered siRNAs are ex-
creted through the kidney, thus it seemed 
logical to develop compounds to treat condi-
tions related to a tissue that is seemingly ex-
posed to these compounds following IV ad-
ministration. QPI-1002 is a naked siRNA 
modified with alternate 2’-O-Me on both 
stands targeting p53 under development by 
Quark Pharmaceuticals. This compound has 
completed a phase I clinical study for kidney 
injury in acute renal failure and a phase II for 
the prophylaxis of delayed graft function in 
deceased donor kidney transplant patients. 
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This phase II trial finished in 2014 and failed 
to meet its primary endpoint which aimed a 
30 % relative risk reduction compared to 
placebo. The sponsor, however highlighted, 
that this endpoint was indeed met in a certain 
set of the population. The company is plan-
ning a phase III trial to start in 2015.  
Viral infections 
In terms of safety, targeting an exoge-
nous genome, completely different from that 
of the host organism seems an ideal situa-
tion. Off-target effects are theoretically 
greatly reduced and issues with exaggerated 
pharmacology are not relevant. 
With this in mind several companies are 
developing compounds that target viral ge-
nomes. The most advanced of these com-
pounds is Arrowhead Corporation’s ARC520 
(Wooddell et al., 2013). This compound 
formulated as a two-molecule DPC adminis-
tered by the IV route targets the hepatitis B 
virus (HBV) genome. The formulation is 
composed of a combination of two chemical-
ly stabilized siRNAs conjugated to choles-
terol and a masked hepatocyte targeted pep-
tide that promotes endosomal escape. The 
targeting moiety of the peptide is a NAG as 
overviewed in the “delivery” section of this 
review. The goal of this drug is to achieve a 
functional cure of HBV that is an immune 
clearant state characterized by HBsAg-
negative serum. The mechanism proposed to 
achieve the above mentioned goal is to re-
duce the virus replication and to induce an 
immune response aimed at clearing the virus 
present in the system. The compound was 
tested in a phase 1 dose-escalating study in 
healthy volunteers who received a single 
administration of doses up to 4.0 mg/kg, the 
results of this study showed that the com-
pound was well tolerated with no relevant 
clinical findings. The compound was subse-
quently evaluated in a phase IIa trial in sub-
jects with chronic HBV patients that were 
negative for the antigen e of HBV (HBeAG) 
and under treatment with entecavir, an inhib-
itor of viral replication. The experimental 
treatment was administered as a single dose 
of one four doses or placebo (1.0-4.0 mg/ 
kg); the patients continued on a daily dose of 
entecavir and received an oral dose of anti-
histamines prior to administration of 
ARC520 or placebo to prevent possible skin 
reactions. The interim results of this trial in-
dicated that there was a reduction in the 
HBsAg of 39 % in response to the dose of 
1.0 mg/kg and a 57 % reduction in HBsAg in 
response to the dose of 2.0 mg/kg. The com-
pound was well tolerated at both doses. The 
reduction in the HBsAg in response to the 
dose of 2.0 mg/kg was however below the 
expectations and not sufficient to reduce the 
antigen to levels at which the innate immune 
response can clear the virus achieving a 
functional cure which are estimated to be ap-
proximately 90 % knock-down. The results 
of subsequent doses will point out if the goal 
set out by the company is indeed achievable 
of if further doses of the drug will be re-
quired to accomplish a functional cure.   
TKM-Ebola is a combination of three 
siRNAs that target three genes of the Zaire 
strain of the Ebola virus: the polymerase L, 
VP24 and VP35 (Geisbert et al., 2010). The 
polymerase L interacts with VP35 to gener-
ate the polymerase complex that transcribes 
and replicates the virus genome. VP24 is a 
structural protein; VP24 and VP35 also play 
a role in reducing the host type 1 interferon 
response (Sanchez et al., 1993). The combi-
nation of siRNAs is encapsulated in LNP 
and the final product is a lyophilized powder. 
This compound is being developed under the 
tenets of the animal rule. A phase I study 
was initiated in 2014 to assess the safety, 
tolerability and pharmacokinetics of escalat-
ing doses of TKM-Ebola in healthy volun-
teers. The single dose ascending dose portion 
of the study was completed (0.075-0.5 mg/ 
kg), but prior to starting the multiple dose 
part of the study the FDA issued a hold on 
the program to ask the company to further 
investigate cytokine releases observed in re-
sponse to the single dose. The results of the 
study showed a transient elevation in MCP‐
1, IL‐6, IL‐1 and IL‐8 that returned to base 
levels 24 h post-dosing. Further investiga-
tions indicated that this dose limiting toxicity 
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was present in response to doses higher than 
0.3 mg/kg. The clinical hold has subsequent-
ly been modified to a partial hold to allow 
the drug to be used in infected individuals in 
the current Ebola virus outbreak taking place 
in West Africa.  
 
Programs using local administration 
Skin 
RXI-109, a self-delivery siRNA, targets 
Connective Tissue Growth Factor (CTGF) 
and is being developed for the treatment of 
hypertrophic scaring and keloids. Self-deli-
very siRNAs (sd-siRNA) are asymmetrical 
double stranded RNAs are thought to com-
bine the potency of siRNA with the im-
proved biodistribution of antisense oligonu-
cleotides. RXI-109 is a chemically stabilized 
sd-siRNA that incorporates hydrophobic mo-
ieties for improved cellular uptake (Byrne et 
al., 2013).  The compound was intradermally 
injected in a single dose phase I trial to ana-
lyze safety a preliminary clinical effects of 
the compound. In this trial healthy volun-
teers received an intradermal injection of the 
compound at doses ranging from 1 to 10 mg/ 
incision site into two incision sites in the ab-
domen and placebo into two other sites. In a 
subsequent phase I trial multiple doses of the 
compound (three doses over two weeks) 
were injected into four incisions located on 
one side of the abdomen at doses ranging 
from 2.5 to 7.5 mg/incision and placebo was 
administered via the same route into four in-
cisions on the other side of the abdomen. 
The compound was well tolerated in both 
studies and induced a dose-dependent de-
crease in protein and mRNA levels of CTGF. 
Three phase II studies were initiated in 2013-
2014 to evaluate the efficacy of the com-
pound on lower abdominal scars, keloids and 
hypertrophic scars. Patients of the lower ab-
dominal scar study received the drug on a 
weekly schedule starting immediately after 
surgery (immediate group) or two weeks af-
ter surgery (delayed group). The results re-
leased by the company indicate that blind 
evaluators were able to identify the treated 
side 54 % of the time in the delayed group 
and only 24 % of the time in the immediate 
group at the 3-month follow up visit. The re-
sults in the phase IIa study of lower ab-
dominal scar induced the company to amend 
the keloid and hypertrophic scar studies in 
order to fine-tune the treatment schedule.  
Eye 
The eye offers several advantages as a 
target organ for RNAi therapeutics. It has a 
relatively low content in RNases, and it is 
quite isolated from the rest of the body, lim-
iting the access of the compound adminis-
tered into this organ to systemic circulation 
(Pañeda, 2012). These advantages made the 
eye one of the first targets of RNAi therapeu-
tics. Unfortunately reports of immune stimu-
lation by siRNAs 21 nt or longer diminished 
the initial enthusiasm of RNAi based treat-
ments for ocular conditions (Kleinman et al., 
2008). In the last few years, characterization 
of the specific immune response evoked by 
siRNAs and the development of specific as-
says to investigate this response have al-
lowed recovering some of the initial interest.  
The most advanced programs for ocular 
indications are Quark’s QPI-007 designed to 
silence Caspase 2, currently in Phase II/III 
for the treatment of Non-arteritic Anterior 
Ischemic Optic Neuropathy (NAION) and 
Sylentis’ bamosiran (SYL040012), targeting 
β2-Adrenergic Receptor (ADRB2) for the 
treatment of glaucoma, in phase IIb. QPI-
1007 is a 19-nt modified siRNA that has 
shown to be safe when injected intravitreally 
(IVT) to animal models and humans (Ahmed 
et al., 2011; Solano et al., 2014). The com-
pound is currently being investigated in a 
phase II/III trial to analyze whether multiple 
IVT doses of this compound are able to im-
prove visual acuity in patients suffering 
NAION. Bamosiran is a canonical-designed 
naked siRNA targeting ADRB2 (Pañeda, 
2012, 2013; Martinez et al., 2014). Glauco-
ma is a degenerative, chronic disease of the 
optic nerve that can lead to blindness if left 
untreated (Weinreb and Khaw, 2004). The 
mechanistic details of optic nerve degenera-
tion observed in glaucoma are yet to be fully 
detailed, but it is well established that reduc-
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tion of intraocular pressure avoids develop-
development of the disease. ADRB2 controls 
production and release of aqueous humor, 
the liquid that fills the eye, at the ciliary 
body. This liquid is responsible for providing 
nutrients to the cells inside the eye; it is also 
responsible for maintaining optimal 
intraocular pressure. Treatment with topic 
beta-blockers has shown to efficiently reduce 
intraocular pressure but currently approved 
beta-blockers are small molecules and are 
thus able to reach systemic circulation and 
systemic organs were they cause unwanted 
effects. The rationale behind bamosiran is 
developing a locally active compound that is 
efficient inhibiting ADRB2 in the eye but 
that is not able to reach systemic tissues 
reducing the likelihood of side effects. The 
compound is administered in eye drops and 
has been shown to be well tolerated in 
animal models and humans (Martinez et al., 
2014; Moreno-Montanes et al., 2014). 
Several doses of bamosiran are currently 
being studied in an active controlled phase 
IIb trial. Previous clinical trials with this 
compound have shown promising results in 
healthy individuals and patients with ocular 
hypertension (Moreno-Montanes et al., 2014; 
Pañeda et al., 2014).  
SYL1001 is a naked 19-nt siRNA 
targeting transient receptor potential 
vanilloid-1 (TRPV1) for the treatment of 
ocular pain. TRPV1 is a cation channel 
permeable to calcium activated by stimuli 
such as heat, low pH and capsaicine; this 
receptor is present in several structures of the 
eye where it has been related, among other 
roles, to nociception (Martinez-Garcia et al., 
2013). This compound has shown to be safe 
when administered in eye drops to animals 
models and humans and is undergoing a 
phase I/II for the treatment of ocular pain 
associated to dry eye disease, a condition for 
which no specific treatment currently exists 
(Pañeda, 2012).  
 
STEPS TOWARDS INNOVATION  
The encouraging advances observed in 
the clinical setting have enabled further 
research in the field of RNAi therapeutics. 
Most preclinical pipelines are taking ad-
advantage of the discoveries and lessons 
learned from the compounds that are 
currently advancing though clinical trials. 
Problems identified in developmental 
programs of both siRNAs and ASOs have 
been taken back to the lab in order to find 
innovative ways of solving them. As such, a 
great deal of programs in preclinical research 
are taking advantage of the innovations made 
to facilitate delivery of siRNA based 
compounds to the liver; but we are also 
starting to see new approaches to deliver 
siRNAs to organs outside the liver, 
incorporation of algorithms to reduce 
toxicity, instability etc. Table 3 summarizes 
candidates that are currently advancing 
towards clinical validation.  
 
Table 3: Programs in preclinical development 
Targeted organ Drug Indication(s) Target(s) Delivery Sponsor 
Liver ALN-PCSSC Hypercholesterolemia PCK9 Gal-Nac STC-
SQ 
Alnylam 




















ALN-GO1 Primary hyperoxaluria 
type 1 
Glycolate oxidase Gal-Nac ESC-
SQ 
Alnylam 
ALN-PDL Chronic liver infection Programmed death Gal-Nac ESC- Alnylam 
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Targeted organ Drug Indication(s) Target(s) Delivery Sponsor 
ligand 1 SQ 
ARC-AAT Alpha-1 Antitrypsin 
deficiency 
Alpha-1-Antitrypsin DPC-SQ Arrowhead 
TKM-ALDH2 Alcohol use disorder Aldehyde 
dehydrogenase 2  
LNP-IV Tekmira 
TKM-GSD Glycogen Storage 
Disorder Type IV 
Undisclosed Undisclosed Tekmira 
TKM-HTG Hypertriglyceridemia 
(Rare Forms) 
Undisclosed Undisclosed Tekmira 
Dermal Undisclosed Aging, wounds Collagenase Undisclosed RXi 
Undisclosed Melasma, PIH, lentigines Tyrosinase Undisclosed RXi 
STP705 Skin Scareless Wound 
Healing 
TGFβ1-COX-2 HKP-NP-topical Sirnaomics 
Ophthalmology Undisclosed Retinal scaring Undisclosed Intraocular RXi 
Undisclosed Corneal scaring Undisclosed Topical RXi 
Undisclosed Macular degeneration Undisclosed Intraocular RXi 
Undisclosed Retinoblastoma Undisclosed Intraocular RXi 
SYL116011 Ocular allergy Undisclosed Topical Sylentis 
TT-211 AMD VEGF-A dd-RNAi-IVT Benitec 
STP601 AMD and retinopathy VEGF-VFGFR1-
VEGF2 
HKP-NP-IVT Sirnaomics 
Lung Atu-111 vascular permeability in 
inflammatory conditions 
Angiopoietin 2 DACC Silence Therapeutics










TKM-HBV Hepatitis B infection HBsAg LNP-IV Tekmira 
TKM-Marburg Marburg infection Marburg NP LNP-IV Tekmira 
Undisclosed Hepatitis B infection Undisclosed ddRNAi Benitec 





Cancer Tribetarna Chemoresistant NSCLC beta III-tubulin ddRNAi Benitec 
STP503 Breast Cancer EGFR-Raf-1-mTOR NP-IV Sirnaomics 
Other diseases Undisclosed Oculopharyngeal 
muscular dystrophy 
Undisclosed ddRNAi Benitec 
Undisclosed Cancer-Assocated Pain PKC gamma ddRNAi-Ith Benitec 
 
 
Alnylam has, in the last few years, been 
very active in incorporating new candidates 
to its preclinical pipeline; particularly 
candidates that target genes that require 
down-regulation in the liver. In the last 
months they have implemented their newly 
presented delivery platform into most of 
their preclinical candidates, hence shifting 
the delivery strategy from one based on 
LNPs to a NAC based delivery. Reasons for 
this shift include a better efficacy/toxicity 
ratio and a patient-friendlier administration 
route: subcutaneous instead in intravenous. 
In addition, the NAC delivery platform is 
fully own by Alnylam, excluding the 
requirement of licensing external intellectual 
property. Among the preclinical candidates 
only one, ALN-PCSsc, uses the first 
generation standard chemistry (STC) NAcs; 
whereas the newer candidates use the 
improved version of this technology: 
enhanced stabilization chemistry (ESC). 
Recent data have also shown that NAC 
conjugated siRNAs can also be administered 
to mice via inhalation using high pressure 
microsprays (Presentation at the 10th OTS 
meeting). The biodistribution of the siRNAs 
and the knock-down of the target gene, 
monitored by measuring the serum levels of 
the encoded protein, appear to be equivalent 
to those observed in response to SQ-
administration. These results open up a new 
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avenue for needle free administration for liv-
liver targeting  
Arrowhead Corporation has recently 
filed a CTA for initiation of clinical trials 
with ACR-ATT, a compound for the 
treatment of alpha-1-antitrypsin deficiency. 
It is expected that clinical trials with this 
compound are also amenable to SQ 
administration. In addition to Alnylam and 
Arrowhead, Tekmira has also launched two 
new preclinical programs (TKM-GSD and 
TKM-HTG) that most likely require 
reduction of gene expression in the liver. 
According to recent press releases these new 
programs might pursue a multi-target 
approach. Multi-targeting is an obvious 
direction for the field, as silencing multiple 
targets in a given disease would most likely 
increase potency. As of today, multi-
targeting has only been approached to tackle 
viral infections (TKM-Ebola, ARC520) 
(Geisbert et al., 2010) and cancer (ALN-
VSP) (Tabernero et al., 2013) but the 
experience accumulated by taking these 
compounds through clinical programs will 
certainly boost multi-targeting approaches 
for other conditions.  
Delivery of compounds outside the liver 
is another of the challenges that the RNAi 
field will face in the upcoming years. A few 
steps towards this direction have already 
been taken and hopefully the fruit of this 
labor will start to generate strategies that can 
be taken into clinical trials in the next few 
years. Examples of this include Silence 
Therapeutics’ Atu111, a compound that 
targets Angiopoietin-2. This compound uses 
a delivery platform of poly-lipoplexes 
developed by the company that has been 
shown to deliver RNAi triggers into the lung 
endothelial cells. Another of the most likely 
goals for this technology is achieving 
delivery to the central nervous system. The 
long-lasting effects of RNAi make this 
difficult-to-reach organ an ideal target for 
RNAi based approaches. Several receptors 
present in the blood-brain barrier, such as the 
transferrin receptor, have been used in order 
to develop delivery strategies for RNAi 
triggers into the central nervous system. 
These techniques need however to be refined 
in order to be fully exploited for therapeutic 
use (Boudreau et al., 2011).  
 
CONCLUSION  
The last decade has witnessed the 
remarkable evolution of the use and 
exploitation of RNA interference with the 
aim of developing therapeutics. It has been a 
rough path characterized by volatility in 
support and funding. The introduction of 
chemical modifications as well as the 
development of innovative carriers with the 
ability of delivering RNAi triggers closer to 
their site of action, have significantly 
improved the pharmaceutical properties of 
these compounds. In addition, the robust of 
long lasting gene knock down seen in several 
human trials has shown that RNA 
interference is in fact a very promising tool 
in the therapeutic landscape. The following 
years will be crucial to see if this technology 
is able to give hold up to the expectations 
and whether RNA interference indeed 
becomes a new class of medicines.   
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